Thiazolidinedione inhibits production of RANTES in a cytokine‐treated human lung epithelial cell line

FEBS Letters

Nakamura, Hiroyuki¹  Ishida, Toshihiko¹  Sayo, Yoshitaka¹  Hosokawa, Hitoshi¹  Imachi, Hitomi¹  Fujita, Jiro¹  Okada, Hiroki¹  Momoi, Atsuko¹  Murao, Koji¹  Sato, Makoto¹  Takahara, Jiro¹ 

[1] First Department of Internal Medicine, Kagawa Medical University, 1750-1, Miki-cho, Kita-gun, Kagawa 761-0793, Japan

关键词: RANTES;    Thiazolidinedione;    Interleukin-1β;    Tumor necrosis factor-α;    Eosinophil;    FBS;    fetal bovine serum;    RT-PCR;    reverse transcription polymerase chain reaction;    RANTES;    regulated upon activation normal T-cell expressed and secreted;    TZD;    thiazolidinedione;    PPAR-γ;    peroxisome proliferator-activated receptor-γ;    IL-1β;    interleukin-1β;    TNF-α;    tumor necrosis factor-α;    15d-PGJ2;    15-deoxy-Δ12;    14 prostaglandin J2;    Dex;    dexamethasone;    ELISA;    enzyme-linked immunosorbent assay;   

DOI  :  10.1016/S0014-5793(99)00678-X

学科分类：生物化学/生物物理

来源: John Wiley & Sons Ltd.

【 摘 要 】

The chemokine RANTES is a potent chemoattractant for eosinophils. RANTES is produced by lung epithelial cells during eosinophil-rich inflammatory diseases such as asthma. In this study, we examined the effects of thiazolidinediones (TZD) on RANTES expression in a human lung epithelial cell line, A549. In A549 cells, interleukin-1β and tumor necrosis factor-α induced endogenous RANTES protein secretion, mRNA expression, and promoter activity. The TZD inhibited these effects. Our data indicate that the suppression of the expression of RANTES can be accomplished by TZD treatment, raising the possibility that TZD might be of therapeutic value in diseases such as asthma.

【 授权许可】

Unknown